WHO Raises Warning Over Acute Lack of Obesity Injections
Under a tenth of individuals who could benefit from weight-loss injections such as Wegovy have access to them, warns the WHO as it publishes its first advice on the medications.
Given over a billion individuals worldwide currently classified as obese, it is calling for broader and more equitable access to these injectable treatments.
According to estimates, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"The latest guidelines recognises that excess weight is a chronic disease that can be treated with holistic and lifelong care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are significant hurdles to widespread access to the jabs that can assist patients in reducing considerable weight, notes the body.
Weight-Loss Drug Shortage
Even under the current most optimistic case, the supply of these medications could only cover around 100 million people – fewer than 10% of eligible patients, as stated by the health organization.
The recommendation urges countries and companies to widen availability, by measures including voluntary licensing.
The intellectual property rights on semaglutide – the primary component of the drug Wegovy – is due to expire in multiple countries in 2026.
How Weight-Loss Jabs Function
These medications replicate a biological compound to reduce digestion speed, reduce hunger and boost feelings of fullness so people reduce food intake.
People commonly see weight reduction in the initial weeks of beginning the once-weekly jabs.
Studies indicates users may see weight return a year later of stopping the drug, as their usual hunger return.
Being above a healthy weight increases your risk for experiencing medical conditions, like diabetes, cardiovascular issues, stroke, and specific malignancies.
Obesity concerns people in every country and was associated with 3.7 million deaths worldwide in 2024, according to the health agency.
